

Labmate (Asia) to represent INFORS HT in India

17 November 2011 | News



INFORS HT, Switzerland, manufacturers of shakers and bioreactors, signed an exclusive agreement with Labmate (Asia), a partnership company that represents the interests of several world leaders in their respective fields in India. INFORS HT presents the most innovative bioreactor range for research, process engineering and small production.

Labmate, with a team of over 75 professionals, provides services all over India with headquarters in Chennai and branches in Delhi, Mumbai, Hyderabad, Bangalore and Kolkata. With the investments in biotechnology and scientific research increasing in view of the ever-increasing promises in areas of nanotechnology, drug discovery and agriculture, the company said it was confident that they will have opportunities to accomplish and grow with its partners.

Workshop on the Web of Process and Regulatory Trends

Merck Millipore organized a two-day workshop on 'The Web of Process and Regulatory Trends' in Bangalore recently as part of its endeavor to support and serve the biopharmaceutical industry in India. Over 150 professionals from companies, such as Biocon, Lupin, Intas, Dr Reddy's, Hospira, Gland Pharma, Strides, Matrix, Promed Research Centre, Cipla, Serum Institute, Kemwell and Indian Immunologicals, participated in the event. Dr Jagashetty, the Drugs Controller of Karnataka, inaugurated the event. Lectures were delivered by 23 eminent professionals from the industry in India and abroad on topics related to current trends in processes and regulations related to the pharma and biotech industry. Dr Kurt Brorson from CDER/ US FDA delivered a lecture to the delegates through a live video conference.

Regulators must be accountable: Kalam

Former president of India Dr APJ Abdul Kalam came out strongly against development and supply of spurious drugs on the sidelines of a national consultation on spurious drugs in New Delhi on October 03, 2011. Citing the importance of having sufficient checks and balances, Dr Kalam said, "The menace has to be eliminated from the root and the best organizations and persons who can play a role are public and private hospitals, nursing homes, clinics and medical practitioners, who should immediately report incidents caused due to spurious or sub-standard medicines to the public domain and ensure that preventive actions are taken before they become a major public health disaster."

Dr Kalam asserted that "the regulators have to become accountable and transparent towards patients and make sure there is proper national database created from reports reaching the Government of India to track the cause and find a solution".

Organized by Partnership for Safe Medicines, the aim of the national consultation meet was to build consensus on the methodology needed to study the volume of spurious and substandard drugs prevalent in the country. Participants included key government officials, regulatory bodies and civil society groups. Deputy Drug Controller General of India Dr D Roy said, "No doubt technology can play a major role in tracking and tracing the menace but the need of the hour is to evolve a more holistic approach involving all stakeholders."

Eli Lilly, Boehringer sign deal

Eli Lilly India and Boehringer Ingelheim India entered into an agreement specific to India to co-promote a portfolio of diabetes compounds, which are either in late-stage development or in the market. The collaboration includes Lilly's insulin analogue, Humalog (Lispro), which is already in the market in India, and Boehringer Ingelheim's oral anti-diabetic agent, Linagliptin, which is yet to be approved for marketing in India.

The alliance will leverage the collective scientific expertise and business capabilities of two leading research-driven pharmaceutical companies to address patient needs arising from growing global diabetes epidemic. Since its launch in 2005, Lilly's Humalog range has become a significant player in the nearly \$30 million Premix & Rapid insulin analog market, according to IMS Indian Pharmaceutical Audit, June 2011.

Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor discovered by Boehringer Ingelheim and developed as an oral once-daily single dose tablet for the treatment of Type 2 diabetes. It is already approved in the US, European Union and Japan, among other countries. "India is clearly a market with great need and huge potential for the treatment of diabetes," said Mr Jacques Tapiero, president, emerging markets business area, Eli Lilly. "This strategic alliance with Boehringer Ingelheim will significantly expand our commercial presence in India."

India Healthcare Excellence Awards

At the third edition of the India Healthcare Excellence Awards 2011, Siro Clinpharm was awarded the Indian Clinical Research Organisation of the Year and Roche India was presented with the Indian Oncology Market Company of the Year. GlaxoSmithKline Pharmaceuticals won the award for the Indian Vaccine Market Company of the Year.

Biocon was voted the Indian Biopharma Company of the Year. Mr Narayanan Suresh, group editor, BioSpectrum, who was part of the jury, gave away the award to Biocon. Jubilant Biosys was adjudged the Indian Contract Research Organization of the Year, the second time in running, after winning the same award in 2010. The awards were co-hosted by Frost & Sullivan and Alexandria Real Estate Equities.

Novozymes to ramp up presence in India

Novozymes, the world's largest producer of industrial enzymes, is planning to strengthen its position in the country following a twin strategy of enhancing its global portfolio and developing local solutions to gain further foothold in the India market.

Sale of enzymes to industries in emerging markets is a strong growth driver for Novozymes. This is one of the reasons for the company to ramp up its presence in countries like India, Brazil and China.